Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical cord mesenchymal stem cells for COVID-19-related pulmonary fibrosis
ChiCTR2000031430Phase 2Recruiting
- Sponsor
- The Fifth Medical Center of the PLA General Hospital
- Start
- Mar 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of human umbilical cord mesenchymal stem cells in coronavirus disease 2019 (COVID-19) and pulmonary fibrosis (PF) (2 arms), sponsored by The Fifth Medical Center of the PLA General Hospital. Primary endpoints: Electrocardiogram, St George's Respiratory Questionnaire score and 18 more. Started Mar 2020; status: recruiting.
02
Drugs
human umbilical cord mesenchymal stem cells
03
Conditions
coronavirus disease 2019 (COVID-19)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on ChiCTR2000031430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031430.